Inhalable nanocatchers for SARS-CoV-2 inhibition

Han Zhang,Wenjun Zhu,Qiutong Jin,Feng Pan,Jiafei Zhu,Yanbin Liu,Linfu Chen,Jingjing Shen,Yang Yang,Qian Chen,Zhuang Liu

DOI: https://doi.org/10.1073/pnas.2102957118

IF: 11.1

2021-07-02

Proceedings of the National Academy of Sciences

Abstract:Significance The recently emerged SARS-CoV-2 variants are more transmissible, which brings new challenges to vaccine treatment. There is an urgent global need for alternative strategies that could effectively and rapidly prevent the infection of various SARS-CoV-2 variants. Herein, we design human angiotensin-converting enzyme II (hACE2)–containing nanocatchers (NCs) derived from genetically engineered cells stably expressing hACE2 as the competitor with host cells for virus binding to protect cells from SARS-CoV-2 infection. An inhalable formulation fabricated by NCs and the mucoadhesive excipient hyaluronic acid could significantly prolong the retention of NCs in the lung and exhibits potent pseudovirus inhibition ability in an hACE2-expressing mouse model. Importantly, the inhalable NCs in the lyophilized formulation allow long-term storage, facilitating their future clinical use.

multidisciplinary sciences